Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 15, 2019
Poland and Slovenia Added to EU–US Mutual Recognition Agreement
Author(s)Pharmaceutical Technology Editors
The two countries have been included in the mutual recognition agreement between the EU and US for GMP inspections.
Advertisement
On Feb. 11, 2019, the European Medicines Agency (EMA)
The agreement allows the EU and the US to focus its resources on other parts of the world and prioritize on higher-risk sites. It also reduces administrative burdens and costs that would be incurred by duplicate inspections.
With the addition of Poland and Slovenia, the total number of EU countries involved in the agreement is now at 22 Member States. It is anticipated that all EU Member States will be involved by July 15, 2019.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement